Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Inclusion Criteria: * Histologically proven salivary gland carcinoma (World Health Organization \[WHO\], 2005) arising from a previous head and neck primary site, and located within the head and neck region, lung or bone, and who are not candidates for curative intent therapy * Demonstrated disease progression during, or after discontinuation, of the most recent line of systemic therapy. For patients who have received no prior systemic therapy, demonstrated progression in the 3 months prior to trial participation assessed by the treating physician * Have received any number lines of prior systemic therapy (including systemic therapy in the curative intent setting) * Have a lesion/s deemed suitable by the treating physicians for stereotactic body radiation therapy (SBRT) with the intent of palliation or prevention of symptoms. This lesion must be: * 1-3 non-overlapping sites in the head and neck region OR * Metastatic lesions outside the head and neck (H\&N) region in the lung or bone (a minimum of 1 and a maximum 5 lesions will be irradiated), provided there is no significant overlap between the lesions \*\* Patients should have RECIST 1.1 criteria measurable disease in addition to the lesion/s treated with SBRT. If the site/s of SBRT were previously radiated to high dose radiation therapy (RT) (\> 50Gy), there should be \> 6 month time interval between the last dose of radiation and the start of SBRT * Have the ability to tolerate required SBRT-related procedures (e.g.…